What Percentage of the Population Has an MTHFR Mutation?

Somewhere between 40 and 60 percent of the general population carries at least one copy of a common MTHFR gene variant, making these among the most widespread genetic polymorphisms in humans. The exact percentage depends heavily on which variant you’re talking about, how many copies someone carries, and which ethnic or geographic population you’re looking at. Despite how common these variants are, the clinical significance for most carriers is modest, and the gap between what the internet claims about MTHFR and what the medical evidence supports is wide enough to drive a truck through.

The Two Main Variants and Their Numbers

When people say “MTHFR mutation,” they’re almost always referring to one of two well-studied changes in the MTHFR gene: C677T and A1298C. These aren’t exotic rare mutations. They’re common polymorphisms, meaning they show up frequently enough in human populations that they’re considered normal genetic variation rather than disease-causing anomalies.

For C677T, the picture breaks down by how many copies you carry. Having one copy (being a heterozygous carrier) is very common, affecting roughly 30 to 40 percent of many populations. Having two copies (being homozygous TT) is less common but far from rare. The TT genotype reaches its highest known frequency of about 32 percent in Mexican populations and its lowest, under 2 percent, in people of African and sub-Saharan African descent.¹ For the A1298C variant, homozygous CC status runs around 9 to 10 percent in Caucasian populations, while carrying at least one copy is considerably more common. In some populations the carrier rate for A1298C is strikingly high: a study of the Lebanese population found that about 74 percent of participants carried at least one A1298C variant, the highest prevalence reported for that polymorphism anywhere in the world.²

Then there’s the compound situation: carrying one copy of each variant simultaneously. This double heterozygosity has a prevalence of roughly 15 to 20 percent in the general population.¹ So if you add up everyone carrying at least one variant of either type, you quickly reach a majority of many populations. Calling these “mutations” in casual conversation can give the misleading impression of something rare or dangerous, when in reality they’re part of the ordinary spectrum of human genetic diversity.

Why Prevalence Swings So Much by Ethnicity and Geography

One of the most consistent findings in the MTHFR literature is that these variants aren’t distributed evenly around the world. Research on U.S. primary care populations found striking ethnogeographic differences: African-Americans appear to be relatively protected from reduced MTHFR function, carrying these variants at lower rates, while Hispanics and Caucasians show elevated frequencies of C677T and A1298C respectively.³ Populations in southern Europe, East Asia, and Latin America tend to have higher C677T frequencies than those in sub-Saharan Africa.

This geographic pattern isn’t random. Researchers have documented a positive correlation between MTHFR variant frequency and latitude: as you move farther from the equator, both C677T and A1298C become more common.⁴ One proposed explanation ties this to ultraviolet radiation and folate. Closer to the equator, intense UV exposure degrades folate in the blood, so having a fully active MTHFR enzyme that efficiently channels folate into methylation pathways would be advantageous. Farther from the equator, where UV is weaker and folate degradation is less of a problem, the reduced-activity MTHFR variants may carry a different advantage: they shift more folate toward DNA repair pathways (specifically thymidylate synthesis), which could help protect against DNA damage in other ways. The evolutionary story is still being worked out, but the latitude pattern is real and reproducible.

The practical upshot is that a percentage quoted without specifying the population is almost meaningless. Telling someone “about 10 percent of people are homozygous for C677T” would be reasonably accurate for many European and East Asian populations but wildly off for Mexican or African-descended groups. If you’ve had MTHFR testing done, your ethnic background matters for interpreting what the result means in context.

What the MTHFR Enzyme Does and Why Variants Matter

The MTHFR gene provides instructions for making an enzyme called methylenetetrahydrofolate reductase. This enzyme sits at a critical junction in what biochemists call the one-carbon cycle, a set of reactions that the body uses for processing folate, recycling an amino acid called homocysteine back into methionine, and supporting the production of DNA, RNA, and proteins.⁵ Specifically, MTHFR converts one form of folate into another form (5-methyltetrahydrofolate) that the body needs to convert homocysteine into methionine. When the enzyme works at full speed, homocysteine gets efficiently recycled. When enzyme activity is reduced, homocysteine can build up.⁶

The C677T variant produces an enzyme that’s less heat-stable and has reduced activity. People homozygous for this variant (TT genotype) typically retain only about 30 percent of normal enzyme function. The A1298C variant also reduces activity but less dramatically; homozygous individuals for A1298C retain roughly 60 percent of normal enzyme activity. The compound situation, carrying one copy of each variant simultaneously, produces enzyme activity in the 50 to 60 percent range, which is actually lower than what you’d see in someone with just one copy of C677T alone.⁷

Reduced enzyme activity doesn’t automatically mean disease. Many people with significantly reduced MTHFR function live perfectly healthy lives, especially if their folate intake is adequate. The enzyme reduction creates a susceptibility, not a destiny.

Health Conditions Where MTHFR Variants Show Up

The most solidly established health connection is with neural tube defects in pregnancy. A meta-analysis of 25 case-control studies found that mothers carrying the TT genotype for C677T had roughly double the risk of having offspring with neural tube defects compared to mothers with the normal CC genotype.⁸ A separate meta-analysis examining the fetal genotype confirmed that C677T in the developing baby itself also increases neural tube defect risk, with the strongest associations seen in Caucasian and Asian populations.⁹ This is one reason folate supplementation before and during early pregnancy is universally recommended, regardless of MTHFR status.

Elevated homocysteine levels are another well-documented downstream effect. Research has found that people carrying the T allele of C677T tend to have higher homocysteine, and this holds true in both healthy individuals and those with conditions like hypertension.¹⁰ A meta-analysis focused on Parkinson’s disease found that the T allele was associated with higher homocysteine in both patients and controls, and suggested C677T may independently contribute to Parkinson’s risk in European populations.¹¹

Recurrent miscarriage is another area of active research. The proposed mechanism involves how MTHFR variants may impair blood vessel development in the placenta, potentially leading to clot formation in the uterine arteries during the critical early weeks of pregnancy.¹² The connection between MTHFR variants and miscarriage has led some clinicians to suggest folic acid and B vitamin supplements for women with recurrent pregnancy loss who carry these variants, though the evidence base is still limited.¹³

Mental health is a newer and more contentious frontier. A meta-analysis found that C677T is significantly associated with schizophrenia and major depression across the overall population, with the strongest signals appearing in Asian populations. In African populations, a link to schizophrenia was also found. The A1298C variant, by contrast, showed only a marginal connection to major depression.¹⁴ A separate meta-analysis found a statistical association between C677T and autism spectrum disorder regardless of ethnicity, though no such link was found for A1298C.¹⁵ These psychiatric associations are statistically real but effect sizes are modest, meaning MTHFR status is one small piece of a much larger puzzle for any individual.

Why Your Doctor Probably Won’t Order MTHFR Testing

Given how many health conditions have been statistically linked to MTHFR variants, you might expect that testing would be routine. It isn’t, and there’s a specific reason. The American College of Medical Genetics and Genomics (ACMG) published a practice guideline stating that MTHFR polymorphism testing has minimal clinical utility and should not be ordered as part of a routine evaluation for blood clotting disorders.¹⁶ The ACMG subsequently reaffirmed this position in an addendum, underscoring that the evidence had not changed their recommendation.¹⁷

The reasoning is straightforward. Even though MTHFR variants can raise homocysteine levels, and elevated homocysteine has been associated with cardiovascular and clotting problems, knowing someone’s MTHFR genotype doesn’t change what a clinician would do. If a patient has elevated homocysteine, the standard intervention is the same regardless of whether it’s caused by MTHFR variants, poor diet, kidney problems, or something else: ensure adequate folate and B vitamin intake. Testing the gene doesn’t add actionable information beyond what a simple blood test for homocysteine itself would provide.

This creates a frustrating disconnect. Many direct-to-consumer genetic tests report MTHFR status, and patients frequently arrive at their doctor’s office with results in hand, alarmed to learn they carry a “mutation.” Online wellness communities amplify this concern, framing MTHFR variants as a root cause of everything from fatigue and anxiety to infertility and chronic pain. The medical establishment’s position is more restrained: the variants are real, the statistical associations exist, but for the vast majority of carriers the practical response is simply to maintain good nutrition.

How Folate Intake Interacts with MTHFR Status

If MTHFR variants reduce the efficiency of folate processing, it stands to reason that folate intake would matter more for people who carry them. The evidence supports this, but with some nuance. A cross-sectional study in a Japanese population found that higher folate intake was associated with higher blood folate levels in people with the CC or CT genotypes of C677T. However, in people with the TT genotype (the most reduced enzyme activity), the relationship between dietary folate and homocysteine levels was less clear-cut.¹⁸

Research in a Korean population added another dimension: individuals with the TT genotype needed higher folate levels to reach the same protective threshold as CC or CT carriers. When TT individuals had low folate status, their estimated risk of coronary artery disease was elevated, but with adequate folate the risk dropped, though not as cleanly as in other genotypes.¹⁹ The implication is that people with reduced MTHFR activity may need to be more attentive to their folate intake, but that genetic status alone doesn’t determine outcomes. Diet is a powerful modifying factor.

This gene-diet interaction is also why the public health strategy of folate food fortification (mandatory in the U.S. since 1998) has been so effective at reducing neural tube defects across the entire population, not just in women who happen to know their MTHFR status. Raising baseline folate levels lifts all boats, including those of people whose MTHFR enzyme is running at reduced capacity.

The Methylfolate Question

One of the most common follow-up questions from people who learn they carry an MTHFR variant is whether they should take methylfolate (the already-converted form of folate, also called 5-MTHF or L-methylfolate) instead of standard folic acid. The logic is appealing: if your enzyme doesn’t convert folic acid to its active form efficiently, why not skip the conversion step entirely?

In practice, this is more complicated than it sounds. Standard folic acid can enter folate metabolism through more than one pathway, and most people with MTHFR variants still convert enough folic acid to meet their needs, especially at the doses found in fortified foods and standard supplements. Methylfolate supplements are available and are used by some clinicians for patients with documented folate metabolism issues, but the evidence that they produce meaningfully better outcomes than folic acid for the average MTHFR variant carrier is not strong. For women planning pregnancy, the established recommendation remains folic acid supplementation, since that’s what the large prevention trials used. Anyone concerned about their specific situation should discuss it with a healthcare provider rather than self-prescribing based on a genotype result.

MTHFR and DNA Methylation

Beyond homocysteine, one of the theoretically important downstream effects of reduced MTHFR activity is altered DNA methylation. Methylation is a chemical process the body uses to regulate gene expression, essentially switching genes on and off. Since MTHFR helps produce the methyl groups needed for this process, reduced enzyme activity could theoretically lead to under-methylation of DNA, which has been linked in various research contexts to cancer risk and other conditions.

The reality appears more complicated than the theory. A study examining global DNA methylation in oral cells from healthy individuals found no significant differences in methylation levels between people with the CC, CT, and TT genotypes of C677T.²⁰ This doesn’t rule out that methylation effects could appear in specific tissues, at specific life stages, or under conditions of folate deficiency, but it does push back against the idea that MTHFR variants inevitably and broadly impair methylation across the body. The relationship between MTHFR genotype and methylation is likely context-dependent, modulated by diet, age, and tissue type rather than following a simple cause-and-effect chain.

Psychiatric Connections and the Treatment-Resistance Angle

A small but growing body of research has looked at whether MTHFR status relates to how well people respond to psychiatric medications. A retrospective review of 186 outpatient psychiatric patients who were tested for MTHFR found that 85 had moderate MTHFR deficiency and 24 had severe deficiency, while 77 had normal function.²¹ The study examined the relationship between MTHFR status and the number of failed medication trials, probing whether people with reduced enzyme function might be harder to treat with standard antidepressants or other psychiatric drugs.

This line of research is in its early stages, and the study design (retrospective, relatively small) limits the conclusions you can draw. But it reflects genuine clinical curiosity about whether folate metabolism might explain some cases of treatment-resistant depression or anxiety, and whether adding methylfolate to a medication regimen could help some patients who haven’t responded to standard treatment alone. A handful of clinical trials have tested this approach, with mixed but somewhat encouraging results. It’s an area where the science hasn’t settled, and anyone encountering claims of dramatic breakthroughs should remain cautious.

When MTHFR Testing Might Actually Be Useful

Despite the ACMG’s recommendation against routine testing, there are narrow clinical scenarios where knowing MTHFR status could inform care. Neonatal blood clots are one: researchers have noted consistent correlations between MTHFR variants and vascular thrombosis in newborns, a setting where the risk profile is different from adult clotting disorders.¹ In reproductive medicine, some specialists test women with multiple unexplained miscarriages. And in pharmacogenomics, certain chemotherapy drugs interact with folate metabolism in ways that could make MTHFR status relevant to dosing decisions, though this application is still mainly a research interest rather than standard practice.

For most people who discover their MTHFR variant through a consumer genetic test, the most useful response is probably the least dramatic one: eat a diet rich in leafy greens, legumes, and other folate-containing foods, consider a standard prenatal vitamin if pregnancy is planned, and don’t spend hours down an internet rabbit hole reading about methylation protocols. The variants are common precisely because they’re generally compatible with healthy life, especially in populations with adequate nutrition.